These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 20083012)

  • 21. Continuous dopaminergic stimulation and novel formulations of dopamine agonists.
    Stocchi F
    J Neurol; 2011 May; 258(Suppl 2):S316-22. PubMed ID: 21560062
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Continuous dopaminergic stimulation, pulsatile dopaminergic stimulation].
    Destée A; Bordet R
    Rev Neurol (Paris); 2002 Dec; 158 Spec no 1():S69-82. PubMed ID: 12690666
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Should levodopa be used anymore?
    Zegers de Beyl D
    Acta Neurol Belg; 2002 Dec; 102(4):163-6. PubMed ID: 12534242
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa?
    Nutt JG
    Mov Disord; 2007 Jan; 22(1):1-9. PubMed ID: 16958130
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
    Manson AJ; Turner K; Lees AJ
    Mov Disord; 2002 Nov; 17(6):1235-41. PubMed ID: 12465062
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of levodopa-induced motor complications.
    Stocchi F; Tagliati M; Olanow CW
    Mov Disord; 2008; 23 Suppl 3():S599-612. PubMed ID: 18781681
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The rationale for continuous dopaminergic stimulation in advanced Parkinson's disease.
    Nyholm D
    Parkinsonism Relat Disord; 2007 Sep; 13 Suppl():S13-7. PubMed ID: 17707679
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathophysiology of motor fluctuations in Parkinson's disease.
    Widnell K
    Mov Disord; 2005; 20 Suppl 11():S17-22. PubMed ID: 15822108
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gene therapy for Parkinson's disease: an approach to the prevention or palliation of levodopa-associated motor complications.
    Mouradian MM; Chase TN
    Exp Neurol; 1997 Mar; 144(1):51-7. PubMed ID: 9126152
    [TBL] [Abstract][Full Text] [Related]  

  • 30. COMT inhibitors in Parkinson's disease: can they prevent and/or reverse levodopa-induced motor complications?
    Olanow CW; Stocchi F
    Neurology; 2004 Jan; 62(1 Suppl 1):S72-81. PubMed ID: 14718683
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation.
    Jenner P
    Neurology; 2004 Jan; 62(1 Suppl 1):S47-55. PubMed ID: 14718680
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [TBL] [Abstract][Full Text] [Related]  

  • 33. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
    Pearce RK; Banerji T; Jenner P; Marsden CD
    Mov Disord; 1998 Mar; 13(2):234-41. PubMed ID: 9539335
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Management of Parkinson's disease in 2009].
    Maertens de Noordhout A
    Rev Med Suisse; 2009 Aug; 5(214):1650-5. PubMed ID: 19772196
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease.
    Chase TN; Engber TM; Mouradian MM
    Neurology; 1994 Jul; 44(7 Suppl 6):S15-8. PubMed ID: 7519334
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of Parkinson's disease.
    Lieberman A
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):339-43. PubMed ID: 8507903
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dopamine agonists early monotherapy for the delay of development of levodopa-induced dyskinesias.
    Stathis P; Konitsiotis S; Antonini A
    Expert Rev Neurother; 2015 Feb; 15(2):207-13. PubMed ID: 25578445
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Catechol-O-methyltransferase inhibitors in preclinical models as adjuncts of L-dopa treatment.
    Marin C; Obeso JA
    Int Rev Neurobiol; 2010; 95():191-205. PubMed ID: 21095463
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.
    Fox SH; Chuang R; Brotchie JM
    Prog Brain Res; 2008; 172():479-94. PubMed ID: 18772047
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic and pharmacodynamic considerations in management of motor response fluctuations in Parkinson's disease.
    Cedarbaum JM
    Neurol Clin; 1990 Feb; 8(1):31-49. PubMed ID: 2181267
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.